ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • Abstract Number: 1700
    Comparative Effectiveness of Sarilumab vs. Methotrexate as a Glucocorticoid-Sparing Agent in Patients with Polymyalgia Rheumatica
  • Abstract Number: 1362
    Comparative Effectiveness of Upadacitinib versus Other JAK Inhibitors in Patients with Rheumatoid Arthritis in a Global Real-World Setting
  • Abstract Number: 1527
    Comparative Harms in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab or Belimumab: A Multicenter Cohort Study Using the TriNetX Research Network
  • Abstract Number: 1785
    Comparative Immuno-Metabolomics Shows Singular Changes in Systemic Lupus Erythematosus Metabolic Phenotype Induced by T-Cell Activation
  • Abstract Number: 0082
    Comparative Immunology of Entheseal Anchorage Sites Between Spine, Hip and Knee Demonstrates up to 70-fold Greater IL-23 Induction from Axial Enthesis Bone: A New Angle on the Failure of IL-23 Blockade in Ankylosing Spondylitis
  • Abstract Number: 0111
    Comparative Performance of ELISA and CLIA Against the 2023 ACR/EULAR APS Classification Criteria
  • Abstract Number: 0363
    Comparative Risk of Demyelinating Diseases Among Patients on TNF-Alpha Inhibitors: A Cohort Study Using the TriNetX Database
  • Abstract Number: 2640
    Comparative Safety and Use of Non-conventional Combination Targeted Therapy in Adults with Psoriatic Arthritis
  • Abstract Number: 0061
    Comparative Transcriptional Profiling of IPF and RA-ILD Lung Tissue Demonstrates Both Overlapping and Distinct Cell-specific Signaling Pathways
  • Abstract Number: 0320
    Comparative Transcriptional Profiling Reveals Shared Pathway Activation Between Human Jo-1+ Anti-Synthetase Syndrome and Murine Histidyl-tRNA Synthetase-Induced Myositis
  • Abstract Number: 1154
    Comparative Transcriptome Analysis of Murine Model and Human Samples in Anti-Melanoma Differentiation Associated Gene 5 Antibody-positive Rapidly Progressive Interstitial Lung Disease
  • Abstract Number: 2487
    Comparing Circulating Protein Profiles in Patients with Active Myeloperoxidase (MPO) vs Proteinase-3 (PR3) Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis
  • Abstract Number: 0403
    Comparing Domains Reported by Patients and Other Collaborators in CNO and SAPHO: A Qualitative Study and Scoping Review Using the OMERACT Process
  • Abstract Number: 0526
    Comparing Immunogenicity and Safety Following Transition from Reference Rituximab to Biosimilar Rituximab (DRL_RI) in Patients with Rheumatoid Arthritis: A Randomized, Double-blind, Phase 3 Study
  • Abstract Number: 0767
    Comparing Large Vessel Uptake of 68Ga-HA-DOTATATE to 18F-FDG Using PET/CT Imaging in Patients with Active Giant Cell Arteritis
  • « Previous Page
  • 1
  • …
  • 42
  • 43
  • 44
  • 45
  • 46
  • …
  • 182
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology